The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

November 20, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Loperamide Update
As of Sept. 20, the U.S. Food and Drug Administration (FDA) has limited the package sizes for some over-the-counter loperamide products to curb possible abuse. Affected products include Imodium A-D, Imodium Multi-Symptom Relief and Be Health Loperamide HCl Capsules. These changes are due to individuals taking higher than recommended doses of loperamide, effectively abusing the agent.1 Higher loperamide doses may be used to self-treat symptoms of opioid withdrawal or to achieve euphoria.2

You Might Also Like
  • FDA Receives Reports of Loperamide Abuse
  • New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise
  • FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse
Also By This Author
  • Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

Often, individuals use loperamide in combination with other drugs to increase the blood-brain-barrier penetration, inhibit loperamide metabolism and enhance its euphoric effects. Loperamide abuse has led to serious cardiac arrhythmias and death. Although it is safe to use in FDA-approved doses, serious adverse events have occurred in individuals intentionally misusing the drug by taking higher than recommended doses.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Healthcare professionals should be aware that loperamide may cause seemingly unexplained cardiac events, including QT interval prolongation, torsades de pointes or other ventricular arrhythmias, syncope and cardiac arrest. If toxicity is suspected, the patient should immediately discontinue the drug. In some cases of torsades de pointes, electrical pacing or cardioversion may be necessary.

For adults, the new approved maximum daily dose of loperamide is 8 mg daily for over-the-counter products and 16 mg daily for prescription loperamide. This packaging change will hopefully improve the safe use of the agent.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients should be advised to follow the recommended loperamide doses. Patients should also be advised that drug interactions with loperamide increase the risk of serious cardiac events.

Golimumab Biosimilar in Development
In late August, Bio-Thera Solutions announced the start of a phase 1 clinical trial for BAT2506, which is biosimilar to golimumab (Simponi). In the U.S. golimumab is approved to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and ulcerative ulcerative colitis. Other indications for golimumab exist in the European and Chinese markets.3

The clinical trial will compare the pharmacokinetics of BAT2506 with golimumab in healthy volunteers.4 The trial is a randomized, double-blind, two-arm, parallel group study expected to enroll 182 participants. Each patient will receive BAT2506 as a single subcutaneous injection.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Walsh S. FDA in brief: FDA approves new packaging for brand-name over-the-counter loperamide to help curb abuse and misuse. U.S. Food and Drug Administration. 2019 Sep 20.
  2. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns about serious heart problems with high doses of the anti-diarrheal medicine loperamide (Imodium), including from abuse and misuse. 2016 Jun 7.
  3. Bio-Thera Solutions Ltd. Research and development: BAT2506. 2019.
  4. Bio-Thera Solutions Ltd. News release: Bio-Thera Solutions initiates phase 1 clinical Trial for BAT2506, a proposed biosimilar of Simponi (golimumab). 2019 Aug 14.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Safety Tagged With: abuse, BAT2506, FDA, Golimumab, loperamide, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Receives Reports of Loperamide Abuse
  • New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise
  • FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse
  • FDA Releases Biosimilar Guidance, Medicare Will Cover Infliximab-dyyb & More

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.